Orrin Hatch's IP Influence Goes Far Beyond Generic Drugs
Law360Law360
Stephen is a patent litigator whose practice is primarily focused on pharmaceuticals and Paragraph IV disputes under the Hatch-Waxman Act. He has acted as lead counsel for clients in numerous pharmaceutical patent litigations, including cases relating to drugs for the treatment of migraine, sepsis, epilepsy, bipolar disorder, acne, Alzheimer's, ADHD, and pain. He has experience in all phases of Paragraph IV disputes, including the cost-effective management of cases, from pretrial through trial and appeal.
With a strong technical background in life sciences and a particular focus on immunology and molecular biology, Stephen has also handled cases in a variety of other areas, including DNA sequencing, research tools, diagnostics, medical devices, agricultural products, consumer products, and food products.
Patent Litigation
International Trade Commission Litigation
Patent Post-Grant Proceedings
Arbitration
Named an "IP Star" by Managing Intellectual Property, 2014-2017
Recognized as a Texas Super Lawyer (Thomson Reuters), 2014-2018
Law360
Bloomberg Law
Law.com
Global Legal Chronicle
Litigation Daily
Law360
Reuters
Delaware Business Court Insider
Global Legal Chronicle
Litigation Daily
Law360
Law360
Law360
Law360
Nature - Online
Law360
Law360
Law360
Law360
Law360
Law360
Law360
Law360
CDR
law360.com
Tax Update
Baker Botts will be hosting a private reception at the JW Marriott located in San Francisco Union Square on Tuesday January 8, 2019.
On April 23-24, join partners Stephen Hash and Michael O'Shaughnessy for ACI's 12th Annual Paragraph IV Disputes Conference in New York, NY.